Salk Institute President William Brody Joins Governing Board of CIRM
William Brody, president of the Salk Institute for Biological Studies, has been appointed to the Independent Citizens Oversight Committee, the governing board for the California Institute of Regenerative Medicine. Brody succeeds Marsha Chandler, the Salk Institute's executive vice president and chief operating officer, who is stepping down from the board of California's stem cell agency after two years.
As with Chandler before him, Brody was named to the ICOC by California Lt. Gov. John Garamendi.
Brody took the helm of Salk in March, vowing to balance the need for major investments in researchers and their research while maintaining the institute's collegial environment, according to an interview in the July issue of the internal publication Inside Salk.
He joined the institute after serving for 12 years as the 13th president of Johns Hopkins University, telling Inside Salk that: "You can have more wild ideas out here, and discovery is about wild ideas, about challenging the status quo, and that's the excitement of California and of the Salk."
In addition to his Salk duties, Brody sits on the boards of the Commonwealth Fund, Novartis, and IBM and IBM's executive compensation and management resources committee.
Brody began his presidency in 1996 after serving two years as provost for the Academic Health Center at the University of Minnesota. Before becoming provost, Brody held several appointments at Johns Hopkins University School of Medicine from 1987 to 1994, including Martin Donner professor and director of the Department of Radiology, professor of electrical and computer engineering, professor of biomedical engineering and radiologist-in-chief of the Johns Hopkins Hospital.
Brody has been a co-founder of three medical device companies, and served as the president and CEO of Resonex from 1984 to 1987. And from 1977 to 1986, he was professor of radiology and electrical engineering at Stanford University.
A native of Stockton, Calif., Brody received BS and MS degrees in electrical engineering from the Massachusetts Institute of Technology, as well as a PhD in electrical engineering and an MD degree from Stanford. He completed post-graduate training in cardiovascular surgery and radiology at Stanford, the National Institutes of Health, and the University of California, San Francisco.
A private pilot holding airline transport pilot and flight instructor ratings, Brody has earned fellowships at the Institute of Electrical and Electronic Engineers, the American Academy of Arts and Sciences, the American Institute of Biomedical Engineering, the International Society of Magnetic Resonance in Medicine, the American Heart Association, the American College of Radiology, and the American College of Cardiology. He is one of the few individuals to be a member of both the National Academy of Science’s Institute of Medicine as well as its National Academy of Engineering.
Endo Pharmaceuticals President/CEO David Holveck to Deliver Keynote Address at PA-NJ Biotech 2009
David Holveck, president and CEO of Endo Pharmaceuticals, will deliver the keynote address during the Nov. 16 dinner being held as part of Biotech 2009: Imagine. Collaborate. Innovate, the ninth annual joint symposium of BioNJ and Pennsylvania Bio. Holveck’s address is set to focus on the challenge of balancing growth and innovation in healthcare.
[ pagebreak ]
Biotech 2009 will be held Nov. 16-17 at the Pennsylvania Convention Center in Philadelphia. In addition to Holveck's keynote address, the symposium is scheduled to feature panel discussions, two plenary sessions, a luncheon keynote address, partnering sessions, company presentations, an innovation corridor and an exhibit hall.
Holveck joined Endo, which is based in Chadds Ford, Pa., in April 2008 after serving as president of Johnson & Johnson Development Corp., and vice president for corporate development at J&J since 2004. Holveck joined J&J as a company group chairman in 1999, following J&J's acquisition of Centocor, which Holveck helmed as CEO.
NPS Pharmaceuticals CEO Francois Nader to Keynote SoCalBio Investor & Partnership Conference
Francois Nader, president and CEO of NPS Pharmaceuticals in Bedminster, NJ, is set to deliver the luncheon keynote address at the 11th Annual SoCalBio Investor & Partnership Conference, which will be held by the Southern California Biomedical Council, or SoCalBio, on Sept. 17 at the Loews Santa Monica Beach Hotel. Nader plans to address how corporate strategic alliances can foster innovation during and beyond the current weak economy.
Since March 2008 Nader has headed NPS, a biopharmaceutical company focused on the development of new treatments for patients with rare gastrointestinal and endocrine disorders. Nader joined NPS in 2006 as chief medical and commercial officer, advancing the following year to executive vice president and chief operating officer, before joining the company's board of directors in January 2008.
Before joining NPS, Nader was a venture partner at Care Capital, where he also served as chief medical officer of the firm's clinical development capital unit. Earlier he held positions at Aventis Pharmaceuticals, Hoechst Marion Roussel and the Pasteur vaccines division of Rhone-Poulenc. He earned a French State Doctorate in Medicine from St. Joseph University and a Physician Executive MBA from the University of Tennessee.
Forty-five companies have been selected to present at this year's conference, which will also feature breakout sessions whose topics will include alternative models for commercializing life-saving technologies, the dos and don'ts of partnership formation, and tapping government funding for life-science research.